Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy
Journal of Thoracic Oncology(2022)
Abstract
The baseline tumor size (BTS) is known as a prognostic of overall survival (OS) in patients with non-small cell lung cancer (NSCLC) who received immune checkpoint inhibitor monotherapy (ICI-mono). However, prognostic impact of BTS among patients treated with ICI in combination with chemotherapy (ICI-chemo) has not been well investigated.
MoreTranslated text
Key words
Predictive,Immune checkpoint inhibitor (ICI),Baseline tumor burden
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined